Similar articles

• HER2 and response to paclitaxel in node-positive breast cancer.

  Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators. Hayes DF, et al. N Engl J Med. 2007 Oct 11;357(15):1496-506. doi: 10.1056/NEJMoa071167. N Engl J Med. 2007. PMID: 17928597 Clinical Trial.
• Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

  Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Lee KH, et al. BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63. BMC Cancer. 2007. PMID: 17430582 Free PMC article.
• HER2 and response to paclitaxel in node-positive breast cancer.

  Mehta R. Mehta R. N Engl J Med. 2008 Jan 10;358(2):197-8; author reply 198. N Engl J Med. 2008. PMID: 18193531 No abstract available.
• [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].

  Jiang ZF, Shao ZM, Xu BH. Jiang ZF, et al. Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):158-60. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 20403251 Chinese. No abstract available.
• Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.

  Holmes FA. Holmes FA. Semin Oncol. 1996 Oct;23(5 Suppl 11):46-56. Semin Oncol. 1996. PMID: 8893900 Review.